Chromogranin A levels in chronic liver disease and hepatocellular carcinoma

Digestive and Liver Disease

Volumn 41, Issue 1, 2009, Pages 31-35

  Massironi, S ^a   Fraquelli, M ^a   Paggi, S ^a   Sangiovanni, A ^a   Conte, D ^a   Sciola, V ^a   Ciafardini, C ^a   Colombo, M ^a   Peracchi, M ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Chromogranin A; Chronic liver disease; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; CHROMOGRANIN A;

ADULT; AGED; ARTICLE; CANCER SCREENING; CHEMOLUMINESCENCE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHROMOGRANIN A; FEMALE; HEPATITIS, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 57649099444     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.05.002     Document Type: Article

References (29)

1. Sangiovanni A., Del Ninno E., Fasani P., De Fazio C., Ronchi G., Romeo R., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126 (2004) 1005-1014
2. Bruix J., and Llovet J.M. Hepatocellular carcinoma: is surveillance cost effective?. Gut 48 (2001) 149-150
3. Gupta S., Bent S., and Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 139 (2003) 46-50
4. Colli A., Fraquelli M., Casazza G., Massironi S., Colucci A., Conte D., et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101 (2006) 513-523
5. Deftos L.J. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 12 (1991) 181-187
6. Zatelli M.C., Torta M., Leon A., Ambrosio M.R., Gion M., Tomassetti P., et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 14 (2007) 473-482
7. Peracchi M., Conte D., Gebbia C., Penati C., Pizzinelli S., Arosio M., et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol 148 (2003) 39-43
8. Tomassetti P., Migliori M., Simoni P., Casadei R., De Iasio R., Corinaldesi R., et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 13 (2001) 55-58
9. Seregni E., Ferrari L., Bajetta E., Martinetti A., and Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 12 (2001) S69-S72
10. Tropea F., Baldari S., Restifo G., Fiorillo M.T., Surace P., and Herberg A. Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours. Clin Drug Investig 26 (2006) 715-722
11. Huang X.F., Wang C.M., Dai X.W., Li Z.J., Pan B.R., Yu L.B., et al. Expressions of chromogranin A and cathepsin D in human primary hepatocellular carcinoma. World J Gastroenterol 6 (2000) 693-698
12. Nakajima K., Sakurai A., Katai M., Yajima H., Mori J., Katakura M., et al. Chromogranin A expression in hepatocellular carcinoma in a patient with germline MEN1 gene mutation. Intern Med 39 (2000) 20-24
13. Spadaro A., Ajello A., Morace C., Zirilli A., D'Arrigo G., Luigiano C., et al. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 11 (2005) 1987-1990
14. Leone N., Pellicano R., Brunello F., Rizzetto M., and Ponzetto A. Elevated serum chromogranin A in patients with hepatocellular carcinoma. Clin Exp Med 2 (2002) 119-123
15. Taupenot L., Harper K.L., and O'Connor D.T. The chromogranin-secretogranin family. N Engl J Med 348 (2003) 1134-1149
16. Peracchi M., Gebbia C., Basilisco G., Quatrini M., Tarantino C., Vescarelli C., et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 152 (2005) 443-448
17. Talwalkar J.A., and Gores G.J. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 127 (2004) S126-S132
18. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
19. Llovet J.M., Brú C., and Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999) 329-338
20. Grandberg D., Wilander E., Stridsberg M., Granerus G., Skogseid B., and Oberg K. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 43 (1998) 223-228
21. Peracchi M., Tagliabue R., Quatrini M., and Reschini E. Plasma pancreatic polypeptide response to secretin. Eur J Endocrinol 141 (1999) 47-49
22. Black E.R., Panzer R.J., Mayewski R.J., and Griner P.F. Characteristics of diagnostic tests and principles for their use in quantitative decision making in diagnostic strategies for common medical problems. In: Black E.R., Bordley D.R., Tape T.G., and Panzer R.J. (Eds). Diagnostic strategies for common medical problems. 2nd ed. (1999), American College of Physicians, Philadelphia 1-17
23. Sackett D.L., and Haynes R.B. The architecture of diagnostic research. BMJ 324 (2002) 539-541
24. Lijmer J.G., Mol B.W., Heisterkamp S., Bonsel G.J., Prins M.H., van der Meulen J.H., et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282 (1999) 1061-1066
25. Leon A., Torta M., Dittadi R., degli Uberti E., Ambrosio M.R., Delle Fave G., et al. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study. Int J Biol Markers 20 (2005) 156-168
26. Reynaert H., Rombouts K., Vandermonde A., Urbain D., Kumar U., Bioulac-Sage P., et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 53 (2004) 1180-1189
27. Kouroumalis E., Skordilis P., Thermos K., Vasilaki A., Moschandrea J., and Manousos O.N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42 (1998) 442-447
28. Cebon J., Findlay M., Hargreaves C., Stockler M., Thompson P., Boyer M., et al. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 95 (2006) 853-861
29. Dimitroulopoulos D., Xinopoulos D., Tsamakidis K., Zisimopoulos A., Andriotis E., Panagiotakos D., et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 13 (2007) 3164-3170